COVID-19 Treatment

Treatment for COVID-19 with Monoclonal Antibodies (mAbs)

Monoclonal antibodies (mAbs) are given as treatment for COVID-19 to reduce severity and mortality.

REGEN-COV (casirivimab and imdevimab) is the medicine used for treatment of or post-exposure prevention of COVID-19. It is administered wither through a vein (intravenous or IV) or injected in the tissue just under the skin (subcutaneous injections).

Adults and adolescents that have tested positive may visit the COVID-19 Treatment Center to receive the mAbs. A test can be performed on site for those that have not been tested yet but believe they are COVID-19 positive.

Phone:

Appointments are required and can be made by calling 662-579-0136.

Location:

Located next to Cleveland Walk-In Care in Cleveland Medical Mall
810 East Sunflower Road, Suite 100-E
Cleveland, MS 38732

Masks are required within the facility, and enhanced cleaning is taking place to ensure a safe environment for all.

What is casirivimab and imdevimab or monoclonal antibody treatment?

Casirivimab and imdevimab is a monoclonal antibody therapy to help treat non-hospitalized patients with a mild or moderate case of COVID-19 (SARS-CoV-2). Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful viruses. This therapy is designed to help block the COVID-19 virus and prevent the virus from further infecting healthy cells.

Casirivimab and imdevimab have received emergency use authorization (EUA) from the Food and Drug Administration (FDA).

Who is a candidate for monoclonal antibody treatment?

Adults and adolescents 12 years of age or older with mild to moderate symptoms who weigh 88 pounds (40 kg) or more, and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.

Patients must meet specific clinical criteria including:

• Lab-confirmed COVID-19 positive test
• Stable enough to not require hospitalization
• Be within 10 days of symptom onset
• Been exposed to a COVID-19-positive patient and meets the risk profile for benefiting from the therapy

In addition to meeting the above criteria, patients must also have an order from a provider to receive this treatment.

Who is not a candidate for this treatment?

This treatment will not be considered for patients who are currently hospitalized due to COVID-19, require oxygen therapy for COVID-19, and/or have a known hypersensitivity to casirivimab and imdevimab.

How do I qualify for this treatment?

This therapy requires an order from a healthcare provider.

You may:

1. Contact your primary care physician (PCP) to make an appointment, OR
2. Call our Provider Referral Line (PRL) at 662.339.3178 or visit our Find a Doctor feature.

What should I expect?

You will be receiving your treatment at the treatment center is conveniently located next to Cleveland Walk-In Care at 810 East Sunflower Road, inside Cleveland Medical Mall. Treatment is administered either by intravenous route (using IV therapy) or by subcutaneous injections. Patients receiving treatment at the COVID-19 Treatment Center will be required to stay for a duration of up to 2 hours.
 

Important facts about casirivimab and imdevimab

For information on the authorized use of casirivimab and imdevimab and mandatory requirements under the Emergency Use Authorization, please review:

Fact Sheet for REGEN-COV (ENGLISH)

FACT SHEET FOR REGEN-COV (SPANISH)